{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:49:09Z","timestamp":1775868549782,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006510","name":"Duke University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006510","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpurol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pediatric Urology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jpurol.2019.03.011","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T13:33:29Z","timestamp":1553088809000},"page":"441.e1-441.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Immune expression in children with Wilms tumor: a pilot study"],"prefix":"10.1016","volume":"15","author":[{"given":"E.K.","family":"Holl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7731-963X","authenticated-orcid":false,"given":"J.C.","family":"Routh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6455-6401","authenticated-orcid":false,"given":"A.W.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Frazier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.E.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.T.","family":"Tracy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.K.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpurol.2019.03.011_bib1","first-page":"7","article-title":"Cancer statistics","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jpurol.2019.03.011_bib2","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1200\/JCO.2005.01.2799","article-title":"Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group","volume":"23","author":"Grundy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpurol.2019.03.011_bib3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/pbc.21267","article-title":"Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group","volume":"50","author":"Malogolowkin","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jpurol.2019.03.011_bib4","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.1995.13.8.1851","article-title":"Second malignant neoplasms following treatment for Wilm's tumor: a report from the National Wilms' Tumor Study Group","volume":"13","author":"Breslow","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpurol.2019.03.011_bib5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2014.56.1373","article-title":"Individual prediction of heart failure among childhood cancer survivors","volume":"33","author":"Chow","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpurol.2019.03.011_bib6","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1200\/JCO.2008.18.6981","article-title":"Early and late mortality after diagnosis of wilms tumor","volume":"27","author":"Cotton","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpurol.2019.03.011_bib7","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2001.19.7.1926","article-title":"Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group","volume":"19","author":"Green","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpurol.2019.03.011_bib8","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1200\/JCO.2009.27.2922","article-title":"Pregnancy outcome after treatment for Wilms tumor: a report from the national Wilms tumor long-term follow-up study","volume":"28","author":"Green","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpurol.2019.03.011_bib9","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.2003.04.085","article-title":"Pregnancy outcome of partners of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study","volume":"21","author":"Green","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpurol.2019.03.011_bib10","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1002\/cncr.28908","article-title":"Breast cancer in female survivors of Wilms tumor: a report from the national Wilms tumor late effects study","volume":"120","author":"Lange","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.jpurol.2019.03.011_bib11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/pbc.24419","article-title":"Children's Oncology Group's 2013 blueprint for research: renal tumors","volume":"60","author":"Dome","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jpurol.2019.03.011_bib12","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/cgt.2009.39","article-title":"Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy","volume":"16","author":"Boczkowski","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jpurol.2019.03.011_bib13","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1158\/1078-0432.CCR-06-2129","article-title":"Survivin and B7-H1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma","volume":"13","author":"Krambeck","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jpurol.2019.03.011_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jpurol.2019.03.011_bib15","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpurol.2019.03.011_bib16","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1073\/pnas.0406351101","article-title":"Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target","volume":"101","author":"Thompson","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jpurol.2019.03.011_bib17","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.juro.2008.01.056","article-title":"Utility of B7-H1 expression for wilms' tumor: correlation with tumor biology and disease recurrence","volume":"179","author":"Routh","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2019.03.011_bib18","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.juro.2012.11.012","article-title":"B7-h1 as a biomarker for therapy failure in patients with favorable histology Wilms tumor","volume":"189","author":"Routh","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2019.03.011_bib19","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.intimp.2018.12.018","article-title":"Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1\/PD-L1 inhibitors) treatments for urothelial carcinoma patients: a meta-analysis","volume":"67","author":"Rui","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jpurol.2019.03.011_bib20","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.juro.2016.05.100","article-title":"Biomarkers for Wilms tumor: a systematic review","volume":"196","author":"Cone","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2019.03.011_bib21","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1542\/peds.61.4.604","article-title":"Chromosomal imbalance in the Aniridia-Wilms' tumor association: 11p interstitial deletion","volume":"61","author":"Riccardi","year":"1978","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpurol.2019.03.011_bib22","first-page":"711","article-title":"Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5","volume":"44","author":"Koufos","year":"1989","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jpurol.2019.03.011_bib23","first-page":"2331","article-title":"Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome","volume":"54","author":"Grundy","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.jpurol.2019.03.011_bib24","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.ejca.2009.01.005","article-title":"Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study","volume":"45","author":"Messahel","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jpurol.2019.03.011_bib25","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1054\/bjoc.2001.2146","article-title":"The prognostic significance of apoptosis-associated proteins BCL-2, BAX and BCL-X in clinical nephroblastoma","volume":"85","author":"Ghanem","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jpurol.2019.03.011_bib26","first-page":"4265","article-title":"Expression and prognostic value of Wilms' tumor 1 and early growth response 1 proteins in nephroblastoma","volume":"6","author":"Ghanem","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jpurol.2019.03.011_bib27","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.urology.2004.12.005","article-title":"Prognostic markers in nephroblastoma (Wilms' tumor)","volume":"65","author":"Ghanem","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.jpurol.2019.03.011_bib28","doi-asserted-by":"crossref","first-page":"E1267","DOI":"10.1073\/pnas.1105034109","article-title":"Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition","volume":"109","author":"Bielen","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jpurol.2019.03.011_bib29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/ng0594-91","article-title":"Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations","volume":"7","author":"Bardeesy","year":"1994","journal-title":"Nat Genet"},{"key":"10.1016\/j.jpurol.2019.03.011_bib30","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0022-3476(05)80839-X","article-title":"Denys-Drash syndrome: relating a clinical disorder to genetic alterations in the tumor suppressor gene WT1","volume":"123","author":"Coppes","year":"1993","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpurol.2019.03.011_bib31","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.juro.2012.09.115","article-title":"p53 Immunohistochemistry expression in Wilms tumor: a prognostic tool in the detection of tumor aggressiveness","volume":"189","author":"Franken","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2019.03.011_bib32","first-page":"2077","article-title":"Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor","volume":"54","author":"Malkin","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.jpurol.2019.03.011_bib33","doi-asserted-by":"crossref","first-page":"e27059","DOI":"10.4161\/onci.27059","article-title":"Dendritic cell-based immunotherapy in ovarian cancer","volume":"2","author":"Coosemans","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jpurol.2019.03.011_bib34","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature14320","article-title":"Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients","volume":"519","author":"Mitchell","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jpurol.2019.03.011_bib35","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.4103\/2152-7806.151341","article-title":"Immunotherapy for malignant glioma","volume":"6","author":"Suryadevara","year":"2015","journal-title":"Surg Neurol Int"},{"key":"10.1016\/j.jpurol.2019.03.011_bib36","doi-asserted-by":"crossref","first-page":"90","DOI":"10.21037\/sci.2016.11.08","article-title":"Wilms tumor 1 peptide vaccination after hematopoietic stem cell transplant in leukemia patients","volume":"3","author":"Hosen","year":"2016","journal-title":"Stem Cell Invest"},{"key":"10.1016\/j.jpurol.2019.03.011_bib37","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.2217\/imt-2016-0031","article-title":"Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer","volume":"8","author":"Koido","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jpurol.2019.03.011_bib38","series-title":"Wilms tumor. Brisbane (AU)","article-title":"Dendritic cell-based cancer immunotherapy targeting wilms' tumor 1 for pediatric cancer","author":"Shimodaira","year":"2016"},{"key":"10.1016\/j.jpurol.2019.03.011_bib39","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2017-04-780155","article-title":"Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia","volume":"130","author":"Anguille","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jpurol.2019.03.011_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan4220","article-title":"Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs","volume":"9","author":"Brown","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jpurol.2019.03.011_bib41","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00262-017-1984-0","article-title":"Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein","volume":"66","author":"Kitagawa","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jpurol.2019.03.011_bib42","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/1744-9987.12694","article-title":"Vaccination of urological cancer patients with WT1 peptide-pulsed dendritic cells in combination with molecular targeted therapy or conventional chemotherapy induces immunological and clinical responses","volume":"22","author":"Ogasawara","year":"2018","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jpurol.2019.03.011_bib43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00262-018-2257-2","article-title":"Phase I\/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer","volume":"68","author":"Zhang","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jpurol.2019.03.011_bib44","doi-asserted-by":"crossref","first-page":"e0130142","DOI":"10.1371\/journal.pone.0130142","article-title":"Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers","volume":"10","author":"Carbognin","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jpurol.2019.03.011_bib45","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2014.58.1041","article-title":"Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab","volume":"33","author":"McDermott","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Journal of Pediatric Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477513119300695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477513119300695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:47:18Z","timestamp":1761486438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1477513119300695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1477513119300695"],"URL":"https:\/\/doi.org\/10.1016\/j.jpurol.2019.03.011","relation":{},"ISSN":["1477-5131"],"issn-type":[{"value":"1477-5131","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune expression in children with Wilms tumor: a pilot study","name":"articletitle","label":"Article Title"},{"value":"Journal of Pediatric Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpurol.2019.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd on behalf of Journal of Pediatric Urology Company.","name":"copyright","label":"Copyright"}]}}